Last reviewed · How we verify

SB8 — Competitive Intelligence Brief

SB8 (SB8) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (monoclonal antibody) / Bevacizumab biosimilar. Area: Oncology.

phase 3 VEGF inhibitor (monoclonal antibody) / Bevacizumab biosimilar VEGF (Vascular Endothelial Growth Factor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

SB8 (SB8) — Samsung Bioepis Co., Ltd.. SB8 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SB8 TARGET SB8 Samsung Bioepis Co., Ltd. phase 3 VEGF inhibitor (monoclonal antibody) / Bevacizumab biosimilar VEGF (Vascular Endothelial Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (monoclonal antibody) / Bevacizumab biosimilar class)

  1. Samsung Bioepis Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SB8 — Competitive Intelligence Brief. https://druglandscape.com/ci/sb8. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: